Xerava Approved to Treat Abdominal Infections
August 27, 2018 – The U.S. FDA has approved Xerava™ (eravacycline), manufactured by Tetraphase Pharmaceuticals, to treat complicated intra-abdominal infections (cIAIs) in adult patients.
According to the manufacturer, Xerava was well tolerated in clinical trials, and demonstrated a high cure rate compared to treatment with ertapenem and meropenem. Patients who could benefit from treatment include those diagnosed with an intra-abdominal abscess, stomach or intestinal perforation, peritonitis, appendicitis, cholecystitis, or diverticulitis.
Prescribers should restrict the use of Xerava to the treatment of infections strongly suspected of being susceptible to its active ingredient, eravacycline. This measure may help to prevent the development of drug-resistant bacteria and maintain the medication’s efficacy. A member of the tetracycline class of antibiotics, Xerava has a recommended dose of 1mg/kg of body weight given every 12 hours for four to 14 days.
Tetraphase has launched Xerava at a wholesale acquisition (WAC) cost of $43.75 per vial.